Difference between revisions of "Selumetinib (Koselugo)"
Jump to navigation
Jump to search
m |
|||
| Line 5: | Line 5: | ||
*[[Low-grade serous ovarian cancer]] | *[[Low-grade serous ovarian cancer]] | ||
| − | *[[ | + | *[[Differentiated thyroid cancer]] |
*[[Uveal melanoma]] | *[[Uveal melanoma]] | ||
| Line 24: | Line 24: | ||
[[Category:Low-grade serous ovarian cancer medications]] | [[Category:Low-grade serous ovarian cancer medications]] | ||
| − | [[Category: | + | [[Category:Differentiated thyroid cancer medications]] |
[[Category:Uveal melanoma medications]] | [[Category:Uveal melanoma medications]] | ||
[[Category:FDA approved in 2020]] | [[Category:FDA approved in 2020]] | ||
Revision as of 18:20, 21 September 2021
Mechanism of action
Inhibits the enzyme MAPK kinase (MEK), specifically the MEK1 and MEK2 subtypes of the enzyme.
Diseases for which it is used
History of changes in FDA indication
Note: this is not an antineoplastic indication. This drug does have some preliminary data in cancer settings.
- 4/10/2020: Approved for pediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
Also known as
- Code name: AZD6244
- Brand name: Koselugo